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Background: Recent epidemiological evidence indicates an association between cardiovascular
diseases and pulmonary fibrosis. The vascular endothelium acts to maintain vascular homeo-
stasis through multiple mechanisms and impaired endothelial function can contribute to the
development, progression and clinical expression of atherosclerosis.
Methods: We consecutively recruited 39 newly-diagnosed chronic interstitial pneumonitis/
fibrosis patients without any specific etiology. We assessed endothelium-dependent vasodilator
response of patients using digital pulse amplitude tonometry and compared the reactive hyper-
emia index (RHI) with age-, sex- and body mass index-matched control subjects (nZ 30). We
further investigated the relationships betweenRHI and clinical characteristics, laboratory cardio-
vascular risk factors, disease-related factors and circulating levels of inflammatory biomarkers.
Results: RHIwas significantly lower in patients with chronic interstitial pneumonitis/fibrosis than
in control subjects (pZ 0.02). While circulating levels of total cholesterol, triglycerides, HbA1c
and fasting glucose did not differ significantly between groups, patients with chronic interstitial
pneumonitis/fibrosis had significantly lower high density lipoprotein levels and higher lowdensity
lipoprotein levels as compared with control subjects. Regarding disease-related factors, RHI wasof Respiratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho,
.: þ81 75 751 3830; fax: þ81 75 751 4643.
-u.ac.jp (T. Handa).
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270 K. Aihara et al.significantly associated with the diffusing capacity for carbonmonoxide, alveolar-arterial oxygen
pressure difference, 6-minwalk distance andend-exercise oxygen saturation. Additionally, circu-
lating levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 were
inversely correlated with RHI.
Conclusions: Weconfirmedapossible linkbetweenpulmonaryfibrosis andcardiovascular diseaseby
demonstrating an impairment of endothelium-dependent vasodilator response, which was signifi-
cantlyassociatedwiththeseverityofpulmonaryfibrosisandcirculating levelsofadhesionmolecules.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
A growing body of epidemiological evidence indicates an
association between cardiovascular diseases and pulmonary
fibrosis.1e4 Although most deaths in idiopathic pulmonary
fibrosis (IPF) are due to a respiratory cause, cardiovascular
events are also reported to be an important cause of
mortality.5,6 There are several possible mechanisms linking
pulmonary fibrosis to cardiovascular disease. For example,
several cytokines including interleukin-1b (IL-1b), IL-8,
tumor necrosis factor-a (TNF-a) and intercellular adhesion
molecule-1 (ICAM-1), all of which have been reported to be
involved in the pathogenesis of pulmonary fibrosis,7e9 also
playakey role in theprocess of atherosclerosis.10 In addition,
the clotting cascade is activated in pulmonary fibrosis and
has been implicated in its pathogenesis.11 Furthermore,
chronic hypoxic stress, to which patients with pulmonary
fibrosis are often exposed, results in irreversible remodeling
of the vasculature and surrounding tissues, characterized by
smooth muscles proliferation and fibrosis.12
The vascular endothelium acts to maintain vascular
homeostasis through multiple mechanisms, and alteration in
its function precedes the development of morphological
atherosclerotic changes.13 Endothelial dysfunction results in
impaired regulation of vascular tone, a prothrombotic state,
and increased production of inflammatory cytokines and
adhesionmolecules, andhence, it is associatedwith the riskof
future cardiovascular events.13 Endothelial function has been
assessed based on the endothelium-dependent vasodilator
response,13 and measurements of this response using digital
pulse volume amplitude has emerged as a noninvasive, auto-
mated quantitative test for endothelial function.14,15
Based on the epidemiological association between
pulmonary fibrosis and cardiovascular disease, we hypothe-
sized that endothelial function would be more impaired
among patients with pulmonary fibrosis and that the impair-
ment would not be explained by the presence of classical
cardiovascular risk factors. In the present study, we assessed
endothelium-dependent vasodilator response in patientswith
pulmonary fibrosis using digital pulse amplitude tonometry
(PAT) andevaluated the relationship betweendisease-related
factors and endothelium-dependent vasodilator response.
Methods
Study subjects
We consecutively recruited 39 newly-diagnosed idiopathic
chronic interstitial pneumonitis/fibrosis patients who visitedKyoto University Hospital. Patients diagnosed as having any
collagen vascular disease or vasculitis, and patients whose
lungdiseaseswerepotentially causedbydrugoroccupational-
environmental exposureswereexcluded.Noneof thepatients
had other pulmonary diseases or a history of cardiovascular
events such asmyocardial infarction or stroke, and nonewere
receiving insulin, corticosteroids or supplementary oxygen
therapy. IPF was diagnosed on the basis of the current official
joint statement on IPF from the American Thoracic Society
(ATS), European Respiratory Society (ERS), Japanese Respi-
ratory Society and Latin American Thoracic Association.16
Age-, sex- and body mass index (BMI)-matched subjects
without lung disease or any previous history of cardiovascular
events were also recruited as controls. This study was
approved by the Ethics Committee of Kyoto University and
informed consent was obtained from all patients.
Arterial blood gas analysis, including arterial partial
pressure of oxygen (PaO2) and arterial partial pressure of
carbon dioxide (PaCO2), was performed while patients were
breathing room air at rest in the supine position. The
alveolar-arterial oxygen pressure difference (A-aDO2) was
calculated according to the standard formula, using
a respiratory exchange ratio of 0.8. The degree of nocturnal
hypoxemia was assessed by oxygen desaturation index (ODI)
using a pulse oximeter (Pulsox-300i, Konica Minolta Inc.,
Osaka, Japan). ODI was calculated by dividing the total
number of oxygen desaturations by the total recording
time, with desaturation defined as a decrease in SpO2 to 4%
or more below the baseline level. Six-minute walk testing
was performed as recommended by ATS guidelines.17
Digital PAT
Endothelium-dependent vasodilator response was assessed
by digital PAT in the fasting state, the principle of which has
been described previously.14,15 Briefly, digital pulse ampli-
tude was continuously recorded with the Endo-PAT 2000
device (Itamar Medical Inc., Caesarea, Israel) placed on the
tip of each index finger and a blood pressure cuff was
placed on one upper arm (study arm), while the contra-
lateral arm served as a control (control arm). After a 5-min
equilibration period, the cuff was inflated to 60 mmHg
above the systolic blood pressure or 200 mmHg for 5-min
and then deflated to induce reactive hyperemia. Pulse
amplitude was recorded electronically in both fingers and
analyzed by a computerized, automated algorithm that
provided the ratio of the average amplitude over a 1-min
time interval starting 1.5-min after cuff deflation divided
by the average amplitude of a 2.5-min time period before
cuff inflation. The calculated ratio reflects the reactive
Table 1 Characteristics of patients and controls.
Patients
(n Z 39)
Controls
(n Z 30)
p value
Sex, male/
female
24/15 20/10 0.80
Age, years 65.0  8.5 62.7  7.6 0.25
BMI, kg/m2 24.2  3.4 23.2  3.2 0.23
Smoking history,
current/
ex/never
7/22/10 5/11/14 0.17
Smoking, pack
years
29.4  27.3 17.5  24.3 0.07
Systolic blood
pressure, mmHg
123.7  12.2 126.5  13.2 0.36
Diastolic blood
pressure, mmHg
73.5  9.8 77.5  11.0 0.12
Heart rate, bpm 61.2  9.4 58.4  5.9 0.16
ODI 3.8  4.0 5.1  2.6 0.14
Diabetic patients 6 2 0.45
Antihypertensive
treatment
9 10 0.42
Statins use 6 2 0.45
Data are presented as number or mean  SD.
BMI, body mass index; ODI, oxygen desaturation index.
Digital reactive hyperemia in pulmonary fibrosis 271hyperemia index (RHI), with a higher index indicating
a higher flow-mediated hyperemic response.
Blood sample collection and laboratory assessments
Samples of peripheral venous blood were collected in the
morning after an overnight fast. Total cholesterol, high
density lipoprotein (HDL), low density lipoprotein (LDL),
triglycerides, HbA1c and fasting glucose were measured as
classical cardiovascular risk factors. C-reactive protein
(CRP) and fibrinogen were also measured as conventional
systemic inflammatory biomarkers.
Serum concentrations of IL-1b, IL-6, IL-8, TNF-a, ICAM-1
and vascular cell adhesion molecule-1 (VCAM-1) in patients
with chronic interstitial pneumonitis/fibrosis were deter-
mined using the Bio-Plex Pro Human Cytokine Assay (Bio-
Rad Laboratories, Hercules, CA, USA) according to the
manufacturer’s instructions.18 Cytokine-specific antibody-
coated beads were used for these experiments. Beads were
read on the Bio-Plex 200 suspension array system, and
cytokine concentrations were automatically calculated
with Bio-Plex Manager Software by a standard curve derived
from a recombinant cytokine standard.
Pulmonary function tests
Pulmonary function tests were performed using a CHESTAC
system (Chest M.I. Inc., Tokyo, Japan). The diffusing
capacity for carbon monoxide (DLCO) was measured using
the single-breath technique. Percent-predicted values
were used for analyses.
Visual scoring of high-resolution computed
tomography (HRCT)
Two independent observers (AK and TK) reviewed the three
HRCT images taken at the level of the aortic arch, the
carina and right inferior pulmonary venous confluence.
Each lobe of the lung was scored on a scale of 0e5 for the
extents of ground-glass opacity (ground-glass score) and
fibrotic opacity (fibrosis score).19 The two observers’ scores
for each lobe were averaged for data analyses.
Statistics
All statistical analyses were performed using JMP version 9
software (SAS Institute, Cary, NC, USA). Continuous vari-
ables are expressed as mean  standard deviation (SD).
Comparisons of variables between two groups were made
by chi-square tests or unpaired t-tests. Relationships
between pairs of variables were analyzed by Pearson’s
correlation coefficient tests. A p value less than 0.05 was
considered to indicate statistical significance.
Results
Characteristics of patients and controls
The clinical characteristics of all subjects are summarized
in Table 1. Among 39 patients with idiopathic chronicinterstitial pneumonitis/fibrosis, 11 had a typical usual
interstitial pneumonia (UIP) pattern on HRCT scan. In the
remaining 28 patients with HRCT results that were atypical
for UIP, 12 patients underwent surgical lung biopsy: 6 had
UIP, 1 had nonspecific interstitial pneumonia, and 5 did not
meet ATS/ERS histopathologic criteria for a specific diag-
nosis of idiopathic interstitial pneumonias.20 There was no
statistically significant difference between groups with
respect to sex, age, BMI, smoking, blood pressure, heart
rate, ODI, prevalence of diabetes and usage rate of anti-
hypertensive agents or statins.
Table 2 shows pulmonary function, arterial blood gas
data and laboratory cardiovascular risk factors in patients
and control subjects. Forced vital capacity (FVC) and DLCO
were significantly lower in chronic interstitial pneumonitis/
fibrosis patients than in control subjects (both p < 0.001)
but there were no significant differences in PaO2, PaCO2 or
A-aDO2. Although total cholesterol and triglycerides levels
were similar in both groups, HDL levels were significantly
lower and LDL levels were significantly higher in idiopathic
chronic interstitial pneumonitis/fibrosis patients than in
control subjects (p Z 0.002 and 0.01, respectively). With
regard to indices of diabetes, HbA1c and fasting glucose
levels were comparable between groups.
RHI and its related factors
As shown in Fig. 1, RHI of idiopathic chronic interstitial
pneumonitis/fibrosis patients was significantly lower than
that of control subjects (1.8  0.4 vs 2.1  0.6, p Z 0.02).
To identify predisposing factors for impaired endothelium-
dependent vasodilator response in idiopathic chronic
interstitial pneumonitis/fibrosis patients, we investigated
Table 2 Pulmonary function, arterial blood gas data and
laboratory cardiovascular risk factors.
Patients
(n Z 39)
Controls
(n Z 30)
p value
Pulmonary function
FVC, % predicted 94.9  18.5 115.0  18.0 <0.001
DLCO, % predicted 51.2  13.0 87.3  13.2 <0.001
Arterial blood gas data
PaCO2, mmHg 41.0  3.3 41.5  3.5 0.62
PaO2, mmHg 83.5  10.7 83.4  11.0 0.98
A-aDO2, mmHg 15.2  11.7 14.8  12.1 0.88
Laboratory cardiovascular risk factors
Total cholesterol,
mg/dl
208.4  34.2 207.0  32.6 0.86
HDL, mg/dl 47.1  11.1 57.6  16.3 0.002
LDL, mg/dl 133.7  30.6 116.7  20.8 0.01
Triglycerides,
mg/dl
127.8  47.9 131.9  92.1 0.81
HbA1c, % 5.7  0.8 5.5  0.5 0.15
Fasting glucose,
mg/dl
105.8  24.9 97.1  20.6 0.13
Data are presented as mean  SD.
FVC, forced vital capacity; DLCO, diffusing capacity for carbon
monoxide; PaCO2, arterial partial pressure of carbon dioxide;
PaO2, arterial partial pressure of oxygen; A-aDO2, alveolar-
arterial oxygen pressure difference; HDL, high density lipopro-
tein; LDL, low density lipoprotein.
Table 3 Correlation coefficients of reactive hyperemia
index with clinical characteristics and laboratory cardio-
vascular risk factors.
All subjects
(n Z 69)
Patients
(n Z 39)
r value p value r value p value
Patient characteristics
Age, years 0.07 0.58 0.12 0.48
BMI, kg/m2 0.24 0.045 0.22 0.19
Smoking, pack years 0.21 0.09 0.03 0.87
ODI 0.01 0.91 0.08 0.64
Laboratory cardiovascular risk factors
Total cholesterol,
mg/dl
0.18 0.13 0.31 0.06
HDL, mg/dl 0.18 0.13 0.21 0.21
LDL, mg/dl 0.09 0.48 0.26 0.11
Triglycerides,
mg/dl
0.03 0.81 0.18 0.26
HbA1c, % 0.12 0.34 0.05 0.77
Fasting glucose,
mg/dl
0.05 0.71 0.06 0.73
BMI, body mass index; ODI, oxygen desaturation index; HDL,
high density lipoprotein; LDL, low density lipoprotein.
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ratory cardiovascular risk factors and disease-related
factors such as pulmonary function, arterial blood gas
data, 6-min walk testing data and HRCT visual scores. In the
entire study population (n Z 69), RHI was significantly
correlated with BMI [r (correlation coefficient) Z 0.24,
p Z 0.045], but not with other variables (Table 3). Within
the patient group (n Z 39), statistically significantFigure 1 Comparison of reactive hyperemia index in controls
(2.1  0.6) and patients with idiopathic chronic interstitial
pneumonitis/fibrosis (1.8  0.4). Horizontal bars indicate mean
values.relationship with RHI was not found in age, BMI, smoking,
ODI or indices of dyslipidemia and diabetes. Regarding
disease-related factors, RHI was significantly correlated
with DLCO (r Z 0.42, p Z 0.008), A-aDO2 (r Z 0.34,
p Z 0.04), 6-min walk distance (r Z 0.38, p Z 0.02), and
end-exercise oxygen saturation (r Z 0.37, p Z 0.03)
(Fig. 2), but not with PaCO2 (r Z 0.26, p Z 0.13), PaO2
(r Z 0.27, p Z 0.11), FVC (r Z 0.17, p Z 0.29), HRCT
ground-glass score (r Z 0.27, p Z 0.10) or HRCT fibrosis
score (r Z 0.02, p Z 0.89) (Table 4).
Next, we assessed whether a significant relationship
between RHI and disease severity also exists in the homo-
geneous subgroup of IPF-confirmed patients. Pulmonary
function, arterial blood gas data, 6-min walk distance and
end-exercise oxygen saturation were not significantly
different between IPF-confirmed patients and other
patients. IPF-confirmed patients had less ground-glass and
more fibrosis scores on HRCT (Supplementary Table 1).
Among IPF-confirmed patients, RHI was significantly corre-
lated with FVC (r Z 0.58, p Z 0.02), DLCO (r Z 0.64,
p Z 0.006), A-aDO2 (r Z 0.50, p Z 0.04), end-exercise
oxygen saturation (r Z 0.53, p Z 0.03) and HRCT fibrosis
score (rZ 0.54, pZ 0.03), but not with PaCO2 (rZ 0.41,
p Z 0.10), PaO2 (rZ 0.40, pZ 0.12), 6-min walk distance
(r Z 0.36, p Z 0.16) or HRCT ground-glass score
(r Z 0.37, p Z 0.14) (Table 4).
Relationships between RHI and circulating
inflammatory biomarkers
To assess the possible role of systemic inflammation in the
impairment of endothelium-dependent vasodilator response
in patients with idiopathic chronic interstitial pneumonitis/
fibrosis, we investigated the associations between RHI and
Figure 2 Scatter diagrams showing the correlation of reactive hyperemia index with DLCO (a), A-aDO2 (b), 6-min walk distance (c)
and end-exercise oxygen saturation (d) in patients with idiopathic chronic interstitial pneumonitis/fibrosis. The r value indicates
the correlation coefficient. Lines indicate regression lines.
Digital reactive hyperemia in pulmonary fibrosis 273circulating levels of inflammatory biomarkers. Since the
concentrations of IL-1b, IL-6 and TNF-a were below detect-
able levels (<1 pg/ml) in more than half of the samples, we
conducted further analyses only for CRP (0.4  0.7 mg/dl),Table 4 Correlation coefficients of reactive hyperemia
index with disease-related factors.
All patients
(n Z 39)
IPF-confirmed
(n Z 17)
r
value
p
value
r
value
p
value
Pulmonary function
FVC, % predicted 0.17 0.29 0.58 0.02
DLCO, % predicted 0.42 0.008 0.64 0.006
Arterial blood gas data
PaCO2, mmHg 0.26 0.13 0.41 0.10
PaO2, mmHg 0.27 0.11 0.40 0.12
A-aDO2, mmHg 0.34 0.04 0.50 0.04
Six-minute walk test
Six-minute walk
distance, m
0.38 0.02 0.36 0.16
End-exercise
oxygen saturation, %
0.37 0.03 0.53 0.03
HRCT scores
HRCT ground-glass
score
0.27 0.10 0.37 0.14
HRCT fibrosis score 0.02 0.89 0.54 0.03
IPF, idiopathic pulmonary fibrosis; FVC, forced vital capacity;
DLCO, diffusing capacity for carbon monoxide; PaCO2, arterial
partial pressure of carbon dioxide; PaO2, arterial partial pres-
sure of oxygen; A-aDO2, alveolar-arterial oxygen pressure
difference; HRCT, high-resolution computed tomography.fibrinogen (344.9 73.0mg/dl), IL-8 (5.4 2.6 pg/ml), ICAM-
1 (237.3  60.8 ng/ml) and VCAM-1 (135.7  25.3 ng/ml)
levels. Significant and near significant negative correlations
were found between RHI and serum levels of ICAM-1
(rZ 0.30, pZ 0.07) and VCAM-1 (rZ 0.42, pZ 0.008),
whereas CRP (rZ0.27, pZ 0.10), IL-8 (rZ 0.01, pZ 0.94)
and fibrinogen (rZ 0.02, p Z 0.92) levels were not signifi-
cantly associated with RHI.
Discussion
The present study demonstrated a significant impairment of
digitally-recorded endothelium-dependent vasodilator
response in patients with idiopathic chronic interstitial
pneumonitis/fibrosis. This impairment was significantly
related to DLCO, A-aDO2, 6-min walk distance and end-
exercise oxygen saturation, all of which were major phys-
iologic indices for the severity of pulmonary fibrosis. Addi-
tionally, circulating levels of ICAM-1 and VCAM-1 correlated
inversely with RHI.
The impairment of endothelium-dependent vasodilator
response in patients with pulmonary fibrosis and its corre-
lation with several functional parameters of disease status
not only support a possible link between pulmonary fibrosis
and cardiovascular disease1e4 but also imply potential
mechanisms for the impairment of vascular function in
pulmonary fibrosis. Reduced exercise performance and
systemic oxygen desaturation with exercise may lead to
sedentary lifestyle or chronic exposures to hypoxia.
Suvorava et al. showed that forced physical inactivity in
young healthy mice induces reduction of endothelium-
dependent vasorelaxation and vascular endothelial nitric
oxide synthase (eNOS) expression.21 In addition, diminished
eNOS expression and NO release in chronic hypoxic human
274 K. Aihara et al.endothelial cells were also noted.22 Thus, reduced exercise
performance and systemic oxygen desaturation with exer-
cise in pulmonary fibrosis can potentially elicit the
impairment of endothelium-dependent vasodilator
response via reduced expression of eNOS in the absence of
other cardiovascular risk factors.
Dysfunctional endothelial cells can induce increased local
production of endothelin-1,23 angiotensin-II24 and plasmin-
ogen activator inhibitor-1,25 all of which are involved in the
pathogenesis of pulmonary fibrosis.26e28 Hence, conversely,
local endothelial dysfunction in the lung could be associated
with the development or progression of fibrosis, thereby
possibly resulting in gas change derangement. Although we
evaluated endothelial function in the extrapulmonary
systemic circulation, which does not necessarily reflect
changes in pulmonary capillaries, it is plausible that, in
patients with pulmonary fibrosis, local endothelial dysfunc-
tion in the pulmonary microcirculation is present and
perpetuates the progression of fibrosis via mediators
released by injured endothelial cells.
The recruitment, adhesion and subsequent trans-
endothelial migration of circulating leukocytes are impor-
tant processes involved in atherosclerosis.29 These
processes are mediated by inflammatory cytokines and
adhesion molecules,10 the expression of which is upregu-
lated in dysfunctional endothelial cells.13 In our population,
the concentrations of IL-1b, IL-6 and TNF-a were below
detectable levels in more than half of the samples and
circulating levels of CRP, fibrinogen and IL-8 were not
significantly associated with RHI. These results suggest that
systemic inflammation is less prominent and may play
a minor role in the impairment of endothelium-dependent
vasodilator response in patients with pulmonary fibrosis.
However, we found significant and near significant negative
correlations between circulating adhesion molecules and
endothelial function, indicating the presence and associa-
tion of dysfunction and inflammation in the vascular
endothelium, although the magnitude might not be great.
Notably, while circulating levels of total cholesterol,
triglycerides, HbA1c and fasting glucose were similar,
patients with chronic interstitial pneumonitis/fibrosis had
significantly lower HDL levels and higher LDL levels than did
control subjects. Although these factors were not signifi-
cantly related to RHI, theymight contribute at least in part to
the development of endothelial dysfunction. It is unclear
whether impaired lipid metabolism is an outcome of
pulmonaryfibrosis itself or of comorbid conditions associated
with pulmonary fibrosis. Local alterations in the lipid
composition of bronchoalveolar lavage fluidwere reported in
animalmodels of bleomycin-induced pulmonary fibrosis,30 as
well as in patients with IPF.31,32 In addition, recent studies
showed that obstructive sleep apnea was prevalent in
patientswith IPF33 and that chronic intermittent hypoxia can
cause circulating lipid levels to increase in relation to the
severity of the hypoxic stimulus.34 Thus, pulmonary fibrosis,
comorbid conditions and metabolic alterations may be
interrelated, but the underlying mechanisms remain to be
elucidated and further studies are needed.
We should mention some of the limitations of the
present study. Firstly, our cohort of patients was relatively
heterogeneous because it also included some patients other
than IPF or those who could not be diagnosed as IPF due tothe lack of surgical lung biopsy. Although further studies
involving more patients with IPF are necessary, RHI was also
significantly correlated with disease severity including FVC,
DLCO, A-aDO2, end-exercise oxygen saturation and HRCT
fibrosis score even in the subgroup of IPF-confirmed
patients. Secondly, the sample size was small and the
impact of pulmonary hypertension, which commonly
complicates the course of IPF,6 was not investigated.
Although the relationships between RHI and several clas-
sical cardiovascular risk factors were not statistically
significant in the present study, there remains a need for
further studies with larger samples to demonstrate that
impaired endothelium-dependent vasodilator response in
pulmonary fibrosis patients is unlikely to be the result of
confounders.
In conclusion, we confirmed a possible link between
pulmonary fibrosis and cardiovascular disease by demon-
strating an impairment of endothelium-dependent vasodi-
lator response in patients with pulmonary fibrosis. Further
knowledge of the presence and pathophysiological rele-
vance of endothelial dysfunction in pulmonary capillaries
may provide a more integrated understanding of the
mechanisms of pulmonary fibrosis.Conflict of interest disclosure
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